Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity

Erez Eitan, Emmette R. Hutchison, Nigel H. Greig, David Tweedie, Hasan Celik, Soumita Ghosh, Kenneth W. Fishbein, Richard G. Spencer, Carl Y. Sasaki, Paritosh Ghosh, Soumen Das, Susheela Chigurapati, James Raymick, Sumit Sarkar, Srinivasulu Chigurupati, Sudipta Seal, Mark P. Mattson

Research output: Contribution to journalArticle

Abstract

Objective: Multiple sclerosis (MS) is a debilitating neurological disorder involving an autoimmune reaction to oligodendrocytes and degeneration of the axons they ensheath in the CNS. Because the damage to oligodendrocytes and axons involves local inflammation and associated oxidative stress, we tested the therapeutic efficacy of combined treatment with a potent anti-inflammatory thalidomide analog (lenalidomide) and novel synthetic anti-oxidant cerium oxide nanoparticles (nanoceria) in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Methods: C57BL/6 mice were randomly assigned to a control (no EAE) group, or one of the four myelin oligodendrocyte glycoprotein-induced EAE groups: vehicle, lenalidomide, nanoceria, or lenalidomide plus nanoceria. During a 23. day period, clinical EAE symptoms were evaluated daily, and MRI brain scans were performed at 11-13. days and 20-22. days. Histological and biochemical analyses of brain tissue samples were performed to quantify myelin loss and local inflammation. Results: Lenalidomide treatment alone delayed symptom onset, while nanoceria treatment had no effect on symptom onset or severity, but did promote recovery; lenalidomide and nanoceria each significantly attenuated white matter pathology and associated inflammation. Combined treatment with lenalidomide and nanoceria resulted in a near elimination of EAE symptoms, and reduced white matter pathology and inflammatory cell responses to a much greater extent than either treatment alone. Interpretation: By suppressing inflammation and oxidative stress, combined treatment with lenalidomide and nanoceria can reduce demyelination and associated neurological symptoms in EAE mice. Our preclinical data suggest a potential application of this combination therapy in MS.

Original languageEnglish (US)
Pages (from-to)151-160
Number of pages10
JournalExperimental Neurology
Volume273
DOIs
StatePublished - Nov 1 2015

Fingerprint

Autoimmunity
Autoimmune Experimental Encephalomyelitis
Multiple Sclerosis
Inflammation
Oligodendroglia
Therapeutics
Axons
Oxidative Stress
Myelin-Oligodendrocyte Glycoprotein
Pathology
Thalidomide
ceric oxide
lenalidomide
Brain
Demyelinating Diseases
Myelin Sheath
Nervous System Diseases
Inbred C57BL Mouse
Oxidants
Nanoparticles

Keywords

  • Cerebral ventricles
  • Cerium oxide nanoparticles
  • Demyelination
  • EAE
  • Multiple sclerosis

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Eitan, E., Hutchison, E. R., Greig, N. H., Tweedie, D., Celik, H., Ghosh, S., ... Mattson, M. P. (2015). Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. Experimental Neurology, 273, 151-160. https://doi.org/10.1016/j.expneurol.2015.08.008

Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. / Eitan, Erez; Hutchison, Emmette R.; Greig, Nigel H.; Tweedie, David; Celik, Hasan; Ghosh, Soumita; Fishbein, Kenneth W.; Spencer, Richard G.; Sasaki, Carl Y.; Ghosh, Paritosh; Das, Soumen; Chigurapati, Susheela; Raymick, James; Sarkar, Sumit; Chigurupati, Srinivasulu; Seal, Sudipta; Mattson, Mark P.

In: Experimental Neurology, Vol. 273, 01.11.2015, p. 151-160.

Research output: Contribution to journalArticle

Eitan, E, Hutchison, ER, Greig, NH, Tweedie, D, Celik, H, Ghosh, S, Fishbein, KW, Spencer, RG, Sasaki, CY, Ghosh, P, Das, S, Chigurapati, S, Raymick, J, Sarkar, S, Chigurupati, S, Seal, S & Mattson, MP 2015, 'Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity', Experimental Neurology, vol. 273, pp. 151-160. https://doi.org/10.1016/j.expneurol.2015.08.008
Eitan, Erez ; Hutchison, Emmette R. ; Greig, Nigel H. ; Tweedie, David ; Celik, Hasan ; Ghosh, Soumita ; Fishbein, Kenneth W. ; Spencer, Richard G. ; Sasaki, Carl Y. ; Ghosh, Paritosh ; Das, Soumen ; Chigurapati, Susheela ; Raymick, James ; Sarkar, Sumit ; Chigurupati, Srinivasulu ; Seal, Sudipta ; Mattson, Mark P. / Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity. In: Experimental Neurology. 2015 ; Vol. 273. pp. 151-160.
@article{ffeee08ea62a49bc8bd3092471541e13,
title = "Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity",
abstract = "Objective: Multiple sclerosis (MS) is a debilitating neurological disorder involving an autoimmune reaction to oligodendrocytes and degeneration of the axons they ensheath in the CNS. Because the damage to oligodendrocytes and axons involves local inflammation and associated oxidative stress, we tested the therapeutic efficacy of combined treatment with a potent anti-inflammatory thalidomide analog (lenalidomide) and novel synthetic anti-oxidant cerium oxide nanoparticles (nanoceria) in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Methods: C57BL/6 mice were randomly assigned to a control (no EAE) group, or one of the four myelin oligodendrocyte glycoprotein-induced EAE groups: vehicle, lenalidomide, nanoceria, or lenalidomide plus nanoceria. During a 23. day period, clinical EAE symptoms were evaluated daily, and MRI brain scans were performed at 11-13. days and 20-22. days. Histological and biochemical analyses of brain tissue samples were performed to quantify myelin loss and local inflammation. Results: Lenalidomide treatment alone delayed symptom onset, while nanoceria treatment had no effect on symptom onset or severity, but did promote recovery; lenalidomide and nanoceria each significantly attenuated white matter pathology and associated inflammation. Combined treatment with lenalidomide and nanoceria resulted in a near elimination of EAE symptoms, and reduced white matter pathology and inflammatory cell responses to a much greater extent than either treatment alone. Interpretation: By suppressing inflammation and oxidative stress, combined treatment with lenalidomide and nanoceria can reduce demyelination and associated neurological symptoms in EAE mice. Our preclinical data suggest a potential application of this combination therapy in MS.",
keywords = "Cerebral ventricles, Cerium oxide nanoparticles, Demyelination, EAE, Multiple sclerosis",
author = "Erez Eitan and Hutchison, {Emmette R.} and Greig, {Nigel H.} and David Tweedie and Hasan Celik and Soumita Ghosh and Fishbein, {Kenneth W.} and Spencer, {Richard G.} and Sasaki, {Carl Y.} and Paritosh Ghosh and Soumen Das and Susheela Chigurapati and James Raymick and Sumit Sarkar and Srinivasulu Chigurupati and Sudipta Seal and Mattson, {Mark P.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.expneurol.2015.08.008",
language = "English (US)",
volume = "273",
pages = "151--160",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity

AU - Eitan, Erez

AU - Hutchison, Emmette R.

AU - Greig, Nigel H.

AU - Tweedie, David

AU - Celik, Hasan

AU - Ghosh, Soumita

AU - Fishbein, Kenneth W.

AU - Spencer, Richard G.

AU - Sasaki, Carl Y.

AU - Ghosh, Paritosh

AU - Das, Soumen

AU - Chigurapati, Susheela

AU - Raymick, James

AU - Sarkar, Sumit

AU - Chigurupati, Srinivasulu

AU - Seal, Sudipta

AU - Mattson, Mark P.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective: Multiple sclerosis (MS) is a debilitating neurological disorder involving an autoimmune reaction to oligodendrocytes and degeneration of the axons they ensheath in the CNS. Because the damage to oligodendrocytes and axons involves local inflammation and associated oxidative stress, we tested the therapeutic efficacy of combined treatment with a potent anti-inflammatory thalidomide analog (lenalidomide) and novel synthetic anti-oxidant cerium oxide nanoparticles (nanoceria) in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Methods: C57BL/6 mice were randomly assigned to a control (no EAE) group, or one of the four myelin oligodendrocyte glycoprotein-induced EAE groups: vehicle, lenalidomide, nanoceria, or lenalidomide plus nanoceria. During a 23. day period, clinical EAE symptoms were evaluated daily, and MRI brain scans were performed at 11-13. days and 20-22. days. Histological and biochemical analyses of brain tissue samples were performed to quantify myelin loss and local inflammation. Results: Lenalidomide treatment alone delayed symptom onset, while nanoceria treatment had no effect on symptom onset or severity, but did promote recovery; lenalidomide and nanoceria each significantly attenuated white matter pathology and associated inflammation. Combined treatment with lenalidomide and nanoceria resulted in a near elimination of EAE symptoms, and reduced white matter pathology and inflammatory cell responses to a much greater extent than either treatment alone. Interpretation: By suppressing inflammation and oxidative stress, combined treatment with lenalidomide and nanoceria can reduce demyelination and associated neurological symptoms in EAE mice. Our preclinical data suggest a potential application of this combination therapy in MS.

AB - Objective: Multiple sclerosis (MS) is a debilitating neurological disorder involving an autoimmune reaction to oligodendrocytes and degeneration of the axons they ensheath in the CNS. Because the damage to oligodendrocytes and axons involves local inflammation and associated oxidative stress, we tested the therapeutic efficacy of combined treatment with a potent anti-inflammatory thalidomide analog (lenalidomide) and novel synthetic anti-oxidant cerium oxide nanoparticles (nanoceria) in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Methods: C57BL/6 mice were randomly assigned to a control (no EAE) group, or one of the four myelin oligodendrocyte glycoprotein-induced EAE groups: vehicle, lenalidomide, nanoceria, or lenalidomide plus nanoceria. During a 23. day period, clinical EAE symptoms were evaluated daily, and MRI brain scans were performed at 11-13. days and 20-22. days. Histological and biochemical analyses of brain tissue samples were performed to quantify myelin loss and local inflammation. Results: Lenalidomide treatment alone delayed symptom onset, while nanoceria treatment had no effect on symptom onset or severity, but did promote recovery; lenalidomide and nanoceria each significantly attenuated white matter pathology and associated inflammation. Combined treatment with lenalidomide and nanoceria resulted in a near elimination of EAE symptoms, and reduced white matter pathology and inflammatory cell responses to a much greater extent than either treatment alone. Interpretation: By suppressing inflammation and oxidative stress, combined treatment with lenalidomide and nanoceria can reduce demyelination and associated neurological symptoms in EAE mice. Our preclinical data suggest a potential application of this combination therapy in MS.

KW - Cerebral ventricles

KW - Cerium oxide nanoparticles

KW - Demyelination

KW - EAE

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84940093278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940093278&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2015.08.008

DO - 10.1016/j.expneurol.2015.08.008

M3 - Article

C2 - 26277686

AN - SCOPUS:84940093278

VL - 273

SP - 151

EP - 160

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -